REZUROCK: payments to doctors
Payments that named REZUROCK as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $2.1M
- Providers
- 1,473
- Transactions
- 4,218
- Average per transaction
- $509
The per-transaction average — $509 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 1,473 providers the average total is $1,457, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Sanofi-aventis U.S. LLC | $1,969,127 | 91.7% |
| Sanofi US Services Inc. | $105,638 | 4.9% |
| Sanofi Pasteur Inc. | $36,572 | 1.7% |
| Sanofi | $28,803 | 1.3% |
| Kadmon Pharmaceuticals LLC | $6,312 | 0.3% |